BMS’ Zeposia and AbbVie’s Skyrizi Shake Up First-Line Prescribing Patterns in the US Ulcerative Colitis and Crohn’s Disease Markets, Spherix Reports
Takeda’s Entyvio, Janssen’s Stelara, and AbbVie’s Humira leave the most on the table when first-line biologic or small molecule agents are prescribed in inflammatory bowel disease EXTON, Pa., November 30, 2022 /PRNewswire/ — US gastroenterologists estimate that just under 60% of their ulcerative colitis (UC) and 55% of their Crohn’s disease (CD) patients treated with a […]
Ophthalmologists Report Need for Education and Cooperation Between Treating Physicians and Referrers for Geographic Atrophy, According to Spherix Global Insights
A high percentage of GA patients are either being seen for the first time, or not returning for follow-up visits due to lack of options according to non-treating clinicians, making the need for timely referrals essential for getting new treatments to patients. With Apellis’ pegcetacoplan nearing the finish line and Iveric Bios’ avacincaptad pegol not […]
Eli Lilly’s Olumiant is Filling a Critical Gap for Severe Alopecia Areata Patients, According to Spherix Global Insights
Despite highly favorable perceptions of the first approved treatment, dermatologists’ desire increased support from Eli Lilly sales representatives EXTON, Pa., November 17, 2022 /PRNewswire/ — On June 13, 2022, Eli Lilly announced the FDA approval of Olumiant for severe alopecia areata (AA), making it the first systemic therapy available in the US to treat the disease. […]
Spherix Global Insights Honored as One of Philadelphia’s Fastest Growing Privately Held Companies for the Fourth Consecutive Year
The Philadelphia100® Forum and the Philadelphia Business Journal recognize Spherix Global Insights among this year’s top companies in the Greater Philadelphia area EXTON, Pa., November 14, 2022 ― For the fourth consecutive year, Spherix Global Insights – a trusted advisor and industry thought partner that provides specialized market insights to the life sciences industry – […]
The Importance of Advocacy and Community Allyship
The World Health Organization (WHO) estimates that at least 2.2 billion people globally have a near or distance vision impairment. In at least 1 billion – or almost half – of these cases, vision impairment could have been prevented or has yet to be addressed.1 The majority of people with vision impairment and blindness are […]
Further Education Needed for the Proper Diagnosis of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the EU5, Spherix Global Insights Reports
Referrals from primary care physicians to rheumatologists are being delayed due to several factors EXTON, Pa., November 10, 2022 /PRNewswire/ – Rheumatologists in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) recognize a disconnect in the diagnosis and referral process for ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients. The lack of […]
Off-Label Avastin (Genentech) Dominates First-Line Biologic Use in Diabetic Retinopathy Despite Eylea’s (Regeneron) Best Efforts to Secure Share in the Space, According to Spherix Global Insights
While Eylea holds the second-place position, newcomer Vabysmo (Genentech) has already captured a small piece of the market and is the anticipated first switch for many current Eylea patients EXTON, Pa., November 3, 2022 – Despite the availability of on-label products to treat diabetic retinopathy (DR), Genentech’s off-label option, Avastin, is the predominant first-line treatment. […]
European Lupus Market Coverage Highlights Pipeline Perceptions and Country Differences in Patient Management, Spherix Reports
Expanded systemic lupus erythematosus (SLE) research in Europe reveals UK physicians perceive a higher unmet need and difficulty in treating SLE patients compared to other EU markets, though prescribe approved advanced therapy options less often EXTON, Pa., October 26, 2022 /PRNewswire/ — Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) […]
Spherix Global Insights Releases the Titles of Four Abstracts to be Presented at American Society of Nephrology (ASN) Kidney Week 2022
Independently funded research on the role of primary care physicians in CKD care, SGLT2 inhibitors and advancing care for IgA nephropathy patients, disparities in clinical trial enrollment, and lupus nephritis co-management are all covered in Spherix’s abstracts EXTON, Pa., October 18 , 2022 /PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in nephrology, is […]
Early Launch Metrics Reveal an Impressive Start for Sanofi/Regeneron’s Dupixent in Eosinophilic Esophagitis, According to Recent Research Conducted by Spherix Global Insights
Despite satisfaction among gastroenterologists and allergists who have trialed the drug, high patient out-of-pocket costs and reimbursement hassles could hamper future prescribing EXTON, Pa., October 14, 2022 /PRNewswire/ – In May of 2022, Sanofi/Regeneron’s Dupixent (dupilumab) was granted approval by the U.S. FDA to treat eosinophilic esophagitis (EoE) in adults and pediatric patients 12 years […]
